Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.51 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28434856 | 0.82 | CYP19A1 (0.44) | MEN1KMT2ANPC1RAB9APTGS2 | |
| SCHEMBL19700916 | 0.81 | CYP1B1 (0.65) | MEN1KMT2ANPC1RAB9AALDH1A3 | |
| SCHEMBL22276766 | 0.81 | SCN4A (0.46) | MEN1KMT2ANPC1RAB9A | |
| SCHEMBL15076038 | 0.80 | MEN1 (0.61) | MEN1KMT2ANPC1RAB9APTGS2 | |
| SCHEMBL19454746 | 0.80 | CHRNB2 (0.53) | KMT2ANPC1RAB9ACA1CA2 | |
| SCHEMBL26354513 | 0.80 | PTGS2 (0.38) | MEN1KMT2ANPC1RAB9APTGS2 | |
| SCHEMBL27903094 | 0.79 | PTGS2 (0.76) | MEN1KMT2ANPC1RAB9APTGS2 | |
| SCHEMBL18925015 | 0.79 | MEN1 (0.64) | MEN1KMT2ANPC1RAB9APTGS2 | |
| SCHEMBL9143504 | 0.79 | KDR (0.50) | MEN1KMT2ANPC1RAB9APTGS2 | |
| SCHEMBL20812238 | 0.77 | HSP90AA1 (0.55) | MEN1KMT2ANPC1RAB9APTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057815-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2025-02-20 | — | — | US | disclosed |
| US-20230390249-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-12-07 | — | — | US | disclosed |
| US-11773129-B2 | Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2023-10-03 | — | — | US | disclosed |
| US-RE49352-E1 | Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220249443-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2022-08-11 | — | — | US | disclosed |
| CN-114601830-A | Carbamoyloxymethyltriazolylcyclohexanes as LPA antagonists | 百时美施贵宝公司 | 2022-06-10 | — | — | CN | disclosed |
| CN-109963843-B | Carbamoyloxymethyltriazolylcyclohexanes as LPA antagonists | 百时美施贵宝公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-3666771-B1 | LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20210244711-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-08-12 | — | — | US | disclosed |
| US-11007180-B2 | Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3472148-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20180333395-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | CHENG PETER TAI WAH (US) | 2018-11-22 | — | — | US | disclosed |
| US-10071078-B2 | Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-09-11 | — | — | US | disclosed |
| WO-2017223016-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-12-28 | — | — | WO | disclosed |
| US-20170360759-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | SYNGENE INTERNATIONAL LIMITED (IN) | 2017-12-21 | — | — | US | disclosed |
| US-20170355727-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | IONIS PHARMACEUTICALS, INC. (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170290809-A1 | ANTIVIRAL AGENTS AND USES THEREOF | GRIFFITH UNIVERSITY (AU) | 2017-10-12 | — | — | US | disclosed |
| US-7977334-B2 | N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity modulator, insulin resistance | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-12 | — | — | US | disclosed |
| US-20090221589-A1 | Use of aminoalcohol derivatives for the treatment of overactive bladder | TRIESELMANN THOMAS | 2009-09-03 | — | — | US | disclosed |
| US-20080234278-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | TRIESELMANN THOMAS | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360759-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | MEN1 3276/4885KMT2A 1637/4885NPC1 463/4885 |
| US-20220249443-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | MEN1 3276/4885KMT2A 1637/4885NPC1 463/4885 |
| US-20210244711-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | MEN1 3276/4885KMT2A 1637/4885NPC1 463/4885 |
| US-20080234278-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | ADRB1, ADRB3, ADRB2 | MEN1 1897/4885KMT2A 4664/4885NPC1 1549/4885 |
| US-20170290809-A1 | ANTIVIRAL AGENTS AND USES THEREOF | RNASE1, ENTPD5, ACE | MEN1 3514/4885KMT2A 3066/4885NPC1 1326/4885 |
| US-11773129-B2 | Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase | NEU1, NEU3, NEU2 | MEN1 1088/4885KMT2A 3830/4885NPC1 352/4885 |
| US-20090221589-A1 | Use of aminoalcohol derivatives for the treatment of overactive bladder | ADRB2, ADRB1, ADRB3 | MEN1 3318/4885KMT2A 3545/4885NPC1 4457/4885 |
| US-11007180-B2 | Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists | LPAR3, LPAR1, LPAR2 | MEN1 3276/4885KMT2A 1637/4885NPC1 463/4885 |
| US-20230390249-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | MEN1 3276/4885KMT2A 1637/4885NPC1 463/4885 |
| US-20250057815-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | MEN1 3276/4885KMT2A 1637/4885NPC1 463/4885 |
| US-20170355727-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | GNE, GALNT1, GALNT6 | MEN1 2964/4885KMT2A 1653/4885NPC1 1267/4885 |
| US-20180333395-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | MEN1 3276/4885KMT2A 1637/4885NPC1 463/4885 |
| US-10071078-B2 | Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists | LPAR3, LPAR1, LPAR2 | MEN1 3276/4885KMT2A 1637/4885NPC1 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.